ACA
TXG icon

Atlas Capital Advisors’s 10x Genomics TXG Stock Holding History

Atlas Capital Advisors’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,234
Closed -$26.2K – 1099
2026
Q1 		$26.2K Hold
1,234
– – ﹤0.01% 725
2025
Q4 		$20.1K Buy
+1,234
New +$18.6K ﹤0.01% 715
2025
Q2 		$14.3K Hold
1,234
– – ﹤0.01% 744
2025
Q1 		$10.8K Hold
1,234
– – ﹤0.01% 796
2024
Q4 		$17.7K Buy
+1,234
New +$19.5K ﹤0.01% 733
2024
Q3 		– Sell
-1,234
Closed -$24K – 959
2024
Q2 		$24K Sell
1,234
-700
-36% -$18.3K ﹤0.01% 674
2024
Q1 		$72.6K Hold
1,934
– – 0.01% 519
2023
Q4 		$108K Buy
1,934
+240
+14% +$10.4K 0.02% 484
2023
Q3 		$69.9K Hold
1,694
– – 0.01% 501
2023
Q2 		$94.6K Hold
1,694
– – 0.01% 482
2023
Q1 		$94.5K Buy
1,694
+166
+11% +$7.75K 0.01% 473
2022
Q4 		$55.7K Buy
1,528
+168
+12% +$5.49K 0.01% 527
2022
Q3 		$38.7K Buy
1,360
+425
+45% +$16.2K 0.01% 570
2022
Q2 		$42.3K Buy
935
+275
+42% +$14.3K 0.01% 586
2022
Q1 		$50.2K Hold
660
– – 0.01% 545
2021
Q4 		$98.3K Hold
660
– – 0.01% 458
2021
Q3 		$96.1K Hold
660
– – 0.02% 448
2021
Q2 		$129K Hold
660
– – 0.02% 420
2021
Q1 		$119K Hold
660
– – 0.02% 398
2020
Q4 		$93.5K Buy
+660
New +$95.8K 0.02% 402

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Atlas Capital Advisors's TXG Position: Q2 2026 in Review

Atlas Capital Advisors sold out of 10x Genomics (TXG) in Q2 2026, closing a stake of 1,234 shares — an estimated $26.2K sold.

Atlas Capital Advisors first reported a position in TXG in Q4 2020 and held it in 20 quarters. The position peaked at $129K in Q2 2021. 390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Atlas Capital Advisors reported no remaining 10x Genomics position as of Q2 2026 after selling out during the quarter.
  • Atlas Capital Advisors sold 1,234 10x Genomics shares in Q2 2026, an estimated $26.2K.
  • Atlas Capital Advisors first reported a position in 10x Genomics in Q4 2020 and held it in 20 quarters.
  • Atlas Capital Advisors's 10x Genomics position peaked at $129K in Q2 2021.
  • 390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Atlas Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.